Search Results

Clinical Trials Network – Aug 3, 2023
The SNMMI Clinical Trials Network provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Increased standardization in trials leads to better data that then results in expanded utilization of radiopharmaceuticals.

Message from the President – Jul 26, 2023
Since the Annual Meeting, SNMMI has been hard at work increasing access to nuclear medicine, planning for upcoming meetings, strengthening its relationships with colleagues around the world, and working with members to develop programs that meet their wants and needs.

CMS Proposes Removal of National Coverage Determination for Beta Amyloid PET – Jul 18, 2023
SNMMI applauds the recent CMS proposal to remove the national coverage determination for beta amyloid PET, ending the coverage with evidence development requirements and allowing MACS to determine appropriate coverage for these scans.

DOE Isotope Program Issues Annual Update – Jul 14, 2023
The DOE Isotope Program has issued an FY2023 annual update for federal agencies and stakeholders.

Advanced Associate Council – Jul 11, 2023

FDA Fully Approves Leqembi for Alzheimers; CMS Unclear on PET Reimbursement – Jul 10, 2023
The FDA has granted full approval to Leqembi (lecanemab); however, CMS has not committed to reimbursement of the needed PET scans.

Dipyridamole Shortage in Canada – Jul 7, 2023
Due to production delays, dypyridamole is currently in short supply in Canada. This shortage poses a significant challenge to healthcare providers across the country, potentially impacting patient care and treatment outcomes.

Pacific Northwest Chapter – Jul 6, 2023
The Pacific Northwest Chapter of SNMMI

Northern California Chapter – Jul 6, 2023
The Northern California Chapter of SNMMI

Central Chapter – Jul 6, 2023
The Central Chapter of SNMMI

Refine by Audience: